TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27250001
Drug: CEFci arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CEFci arm (5‐Fu 200 mg/m(2) daily by 24‐h continuous infusion and epirubicin 100 mg/m(2) and cyclophosphamide 600 mg/m(2) intravenous bolus on day 1)
Study: 27250001
Drug: CEF arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CEF arm (cyclophosphamide 600 mg/m(2), epirubicin 100 mg/m(2), and 5‐Fu 600 mg/m(2) i.v. on day 1)
Study: 27250001
Drug: EC arm
Normalized name: Drive Cast Protec Arm 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC arm (epirubicin 100 mg/m(2) and cyclophosphamide 600 mg/m(2) i.v. on day 1)
Study: 11441423
Drug: Ecopipam 10
Normalized name: Ecopipam
DrugBank: Ecopipam (DB12273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecopipam 10 mg p.o.
Study: 11441423
Drug: Ecopipam 25
Normalized name: Ecopipam
DrugBank: Ecopipam (DB12273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecopipam 25 mg p.o.
Study: 11441423
Drug: Ecopipam 100
Normalized name: Ecopipam
DrugBank: Ecopipam (DB12273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecopipam 100 mg p.o.
Study: 11441423
Drug: Cocaine 25
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 25 mg/70 kg i.v.
Study: 11441423
Drug: Cocaine 50
Normalized name: cocaine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 50 mg/70 kg i.v.
Study: 7523724
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy combined with androgen deprivation
Study: 7523724
Drug: Conformal 3-dimensional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conformal 3-dimensional radiation therapy
Study: 3372718
Drug: Diazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (15 mg daily for 6 weeks)
Study: 31145366
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus fire needle therapy
Study: 25016389
Drug: Procedural sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procedural sedation and analgesia (intravenous midazolam plus fentanyl)
Study: 16816394
Drug: Morphine in
Normalized name: morphine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine in ropivacaine (Group M, n=30)
Study: 8228792
Drug: Immunoadsorption (IMA)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immunoadsorption (IMA) with combined anticoagulation using heparin and citrate
Study: 8228792
Drug: Dextran sulfate
Normalized name: dextran sulfate
DrugBank: Dextran (DB09255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran sulfate adsorption (DSA) with heparin exclusively
Study: 28499657
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Care (dose-matched, goal-oriented)
Study: 17874889
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (STX)
Study: 16449099
Drug: Fluoxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (10 mg/d for the first week, 20 mg/d for the second week)
Study: 16449099
Drug: Clomipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (25 mg/d for the first week, 50 mg/d for the second week)
Study: 9341573
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment arm
Study: 9341573
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment arm
Study: 15983962
Drug: Spironolactone, 50
Normalized name: Spironolactone, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone, 50 mg, orally twice daily for 2 weeks
Study: 8732962
Drug: Dexamethasone 0.05
Normalized name: dexamethasone 0.05 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.05 mg
Study: 8732962
Drug: Dexamethasone 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.125 mg
Study: 8732962
Drug: Dexamethasone 0.25
Normalized name: dexamethasone 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.25 mg
Study: 1815967
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg emiglitate
Study: 6808657
Drug: Phenoxymethylpenicillin 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenoxymethylpenicillin 0.4 g
Study: 6808657
Drug: Phenoxymethylpenicillin 1
Normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethylpenicillin 1 g
Study: 6808657
Drug: Phenoxymethylpenicillin 2
Normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethylpenicillin 2 g
Study: 27814710
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at 80 ppm as an adjunctive therapy for severe malaria
Study: 10077718
Drug: Hypnosis/self-hypnosis (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis/self-hypnosis (5 sessions, half an hour each, weekly intervals)
Study: 10077718
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy (2 sessions, half an hour each, weekly intervals)
Study: 10077718
Drug: Talks to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talks to the doctor (2 sessions, half an hour each, weekly intervals)
Study: 31661693
Drug: Action Observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action Observation Therapy (AOT) for 20 min before 10 min language therapy daily for 4 weeks
Study: 25142820
Drug: Fast dissolving
Normalized name: Mucinex Sinus-Max Day/Night Fast Dissolving Gels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast dissolving oral film formulation of flupentixol dihydrochloride (2% HPMC)
Study: 25142820
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available oral tablets of flupentixol dihydrochloride
Study: 16188958
Drug: Family based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family based behavioural treatment for obese children for two years
Study: 9042993
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg three times daily)
Study: 1497688
Drug: beta-acetyldigoxin oral
Normalized name: acetyldigoxins
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-acetyldigoxin oral solution
Study: 1497688
Drug: beta-acetyldigoxin tablets
Normalized name: acetyldigoxins
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-acetyldigoxin tablets
Study: 31147361
Drug: Acellular porcine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular porcine collagen implant
Study: 28604556
Drug: NeuGcGM3-based vaccine
Normalized name: covid-19, RNA-based vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeuGcGM3-based vaccine (200 μg) administered every 2 weeks for 5 doses, followed by monthly reimmunizations to complete 15 doses, combined with Montanide ISA51 as adjuvant treatment.
Study: 28604556
Drug: NeuGcGM3-based vaccine
Normalized name: covid-19, RNA-based vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeuGcGM3-based vaccine
Study: 23784727
Drug: Non-specific cognitive
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific cognitive treatment combined with cholinesterase inhibitors (ChEIs)
Study: 21737214
Drug: Intranasal methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal methamphetamine (0, 5, 10, 20 and 30 mg)
Study: 21737214
Drug: Alprazolam XR
Normalized name: ALPRAZOLAM 2 mg ORAL TABLET, EXTENDED RELEASE [Alprazolam XR]
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam XR (0 and 1 mg/day)
Study: 15223851
Drug: Vardenafil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (10 mg)
Study: 14517691
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose of IFN-alpha (2.5 MU/m² per day)
Study: 14517691
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of IFN-alpha (5 MU/m² per day)
Study: 7518728
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment for 4 months
Study: 2178522
Drug: Sequential terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential terbutaline (0.25 mg subcutaneously followed by another 0.25 mg subcutaneously)
Study: 2178522
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment (normal saline)
Study: 27928809
Drug: Medical expulsive
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical expulsive therapy (tamsulosin 0.4 mg daily at night, furosemide 20mg, spironolactone 50mg in a single morning dose, potassium magnesium citrate 20Meq three times a day for 12 weeks)
Study: 27928809
Drug: Medical expulsive
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical expulsive therapy
Study: 20443801
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded implants
Study: 20443801
Drug: Early loaded
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loaded implants
Study: 20001450
Drug: Oral posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral posaconazole suspension as antifungal prophylaxis
Study: 15599319
Drug: Everolimus 3
Normalized name: everolimus 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 3 mg/day
Study: 15599319
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 2 g/day
Study: 12486651
Drug: RITM (remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: RITM (remifentanil and intrathecal morphine) anesthesia
Study: 10433573
Drug: Antibiotic regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic regimens (ciprofloxacin, ofloxacin, norfloxacin, trimethoprim‐sulfamethoxazole, nitrofurantoin)
Study: 10433573
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for > or = 3 days
Study: 7725851
Drug: L-asparaginase (L-Ase)
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase (L-Ase) with human antithrombin III (AT III) concentrates as adjuvant treatment
Study: 25956613
Drug: Fenofibrate 300
Normalized name: fenofibrate 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 300 mg daily
Study: 25194004
Drug: Paricalcitol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (1 μg/d for 3 months, uptitrated to 2 µg/d if tolerated)
Study: 25194004
Drug: Nonparicalcitol therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonparicalcitol therapy
Study: 27558280
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil (AZL-M) 40 mg
Study: 23514842
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil (AZL-M) 80 mg
Study: 23514842
Drug: Ramipril (RAM)
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril (RAM) 10 mg
Study: 17942015
Drug: Dexamphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamphetamine (10 mg) administered at the start of each session during one therapy block
Study: 17942015
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered during the other therapy block
Study: 19470174
Drug: Low-dose risperidone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose risperidone
Study: 30228265
Drug: Enzyme mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme mixture containing peptidase, semi alkaline protease, deuterolysin, and cysteine protease derived from Aspergillus oryzae, Aspergillus melleus, Penicillium citrinum, and Carica papaya L.
Study: 20200016
Drug: Episodic amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic amiodarone treatment (1 month peri-cardioversion)
Study: 18854540
Drug: Continuous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous amiodarone treatment
Study: 11185636
Drug: Telmisartan 120
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan 120 mg with digoxin
Study: 1440310
Drug: Combinations of
Normalized name: Combinations of vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combinations of drugs from the first group and those from the 2nd‐4th group
Study: 30957448
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride (25 mg daily for the first 5 days, then 50 mg daily)
Study: 18691778
Drug: Low potassium
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low potassium (<4 mEq/L)
Study: 16522906
Drug: Placebo (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control) group with 5 g rice starch
Study: 11389298
Drug: Draft CDC
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Draft CDC manual entitled, 'Guideline for Vaccine Storage and Handling'
Study: 3313757
Drug: Ibuprofen/paracetamol/codeine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen/paracetamol/codeine combination (Myprodol; Rio Ethicals) 200 mg ibuprofen, 250 mg paracetamol, 10 mg codeine phosphate per tablet
Study: 3313757
Drug: Standard ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ibuprofen treatment regimen (200 mg per tablet)
Study: 31655189
Drug: Oxycodone 15
Normalized name: oxyCODONE 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 15 mg (5 mg, eight hourly)
Study: 29480399
Drug: Resistant dextrin
Normalized name: wheat dextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant dextrin (20g daily for 3 months)
Study: 16551916
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (single shot)
Study: 20807664
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug (control)
Study: 16792646
Drug: Microdermabrasion (MDA)
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microdermabrasion (MDA) in conjunction with a topical retinoid
Study: 9228878
Drug: G II
Normalized name: mu-conotoxin G IIIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: G II knee brace
Study: 3313023
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASS) 2‐5 mg/kg
Study: 3313023
Drug: Flunarizine 5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine 5‐10 mg
Study: 25844615
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium copper chlorophyllin complex (0.066%) applied twice daily for 8 weeks
Study: 25844615
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium copper chlorophyllin complex (0.066%)
Study: 21945737
Drug: Intravenous ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibandronate injection
Study: 21945737
Drug: Intravenous ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibandronate infusion
Study: 16717335
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine (15-mL bolus, starting concentration 0.425%)
Study: 14699020
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 alone (40 mg)
Study: 31209595
Drug: Any anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any anticoagulant use
Study: 28851310
Drug: Anticoagulant non-users
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant non-users
Study: 25964404
Drug: Weekend-only recreational
Normalized name: Mountain Series Weekender Medical KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekend-only recreational drug use
Study: 24888316
Drug: Myrtle fruit
Normalized name: Myrtle blueberry fruit
DrugBank: Bilberry (DB14235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrtle fruit syrup (15 ml daily for 7 days)
Study: 1623994
Drug: Both implants
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both implants
Study: 17571966
Drug: Wheat grass
Normalized name: Wheat grass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat grass juice (WGJ) 60 cc orally daily during the first three cycles of chemotherapy
Study: 8790827
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of flunisolide nasal spray
Study: 8790827
Drug: Original formulation
Normalized name: Zegerid (Original Formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original formulation of flunisolide nasal spray
Study: 3552444
Drug: Control infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control infusion
Study: 26028346
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Ranibizumab and Bevacizumab)
Study: 27763685
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (PTA + SEP)
Study: 19103434
Drug: N-acetylcysteine (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (2400 mg daily) for 4 weeks
Study: 19103434
Drug: Nicotine self-administration
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine self-administration or osmotic minipumps
Study: 7951614
Drug: Triptoreline (Décapeptyl*
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptoreline (Décapeptyl* 3.75 mg)
Study: 16386942
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (800 microg/day), B12 (20 microg/day), and B6 (4 mg/day) during 1 week (n=29)
Study: 3530769
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg X 3 daily
Study: 28716693
Drug: Neurodevelopmental therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental therapy combined with reflexology
Study: 28716693
Drug: Neurodevelopmental therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental therapy alone
Study: 15623951
Drug: Fluconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100 mg once weekly for 12 months with topical ketoconazole cream
Study: 15623951
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg once weekly for 12 months with topical ketoconazole cream
Study: 15623951
Drug: Fluconazole 300
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 300 mg once weekly for 12 months with topical ketoconazole cream
Study: 17217710
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium 50 mg
Study: 11273142
Drug: Enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril maleate 5 mg
Study: 9377073
Drug: Busulfan (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) (CY) in study I
Study: 9377073
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CY) + TBI (200 mg/kg) + antithymocyte globulin (ATG) in study II
Study: 3853581
Drug: Mevinolin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevinolin (both doses)
Study: 3853581
Drug: Mevinolin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevinolin 20 mg BID
Study: 3853581
Drug: Mevinolin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevinolin 10 mg BID
Study: 25314063
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant treatment (observation)
Study: 18388088
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/d increasing to 10 mg
Study: 12453815
Drug: Community-based program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based program to prevent drug use initiation
Study: 1789815
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 mg q.p.m. for group I, 40 mg q.p.m. for group II)
Study: 8422814
Drug: Gemfibrozil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (600 mg b.i.d.)
Study: 26026121
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (36 mg/m2, days 1 and 8) plus oxaliplatin (80 mg/m2, day 1)
Study: 16356598
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate (PCV7) vaccine administered concurrently with DTaP.IPV/Hib and hepatitis B vaccines
Study: 16356598
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate (PCV7) vaccine administered sequentially with DTaP.IPV/Hib and hepatitis B vaccines